Clinical Practice Guidelines   

Skip to end of metadata
Go to start of metadata

 This is an original JCO publication from 2011. Please visit the JCO website to access the full article.

 Use of Chemotherapy Sensitivity and Resistance Assays



Harold J. Burstein, Pamela B. Mangu, Mark R. Somerfield, Deborah Schrag, David Samson, Lawrence Holt, Debra Zelman and Jaffer A. Ajani




  • Use of CSRAs to determine chemotherapy

Target Audience

  • Medical Oncologists


  • CSRAs to select chemotherapeutic agents for individual patients are not recommended outside of the clinical trial setting


  • Systematic review and analysis of the medical literature by an Update Committee.


Recommendation Category2004 and 2011 Recommendations
Use of CSRAsThe use of CSRAs to select chemotherapeutic agents for individual patients is not recommended outside of the clinical trial setting.
Chemotherapy treatment decisionsOncologists should make chemotherapy treatment recommendations on the basis of published reports of clinical trials and a patient's health status and treatment preferences.
Future research: evaluating CSRAs in clinical trialsBecause the in vitro analytic strategy has potential importance, participation in clinical trials evaluating these technologies remains a priorit


  • Abbreviation: CSRA, chemotherapy sensitivity and resistance assays.







ASCO Guideline Disclaimer: The clinical practice guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. (“ASCO”) to assist practitioners in clinical decision making. The information therein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating physician, as the information does not account for individual variation among patients. Recommendations reflect high, moderate or low confidence that the recommendation reflects the net effect of a given course of action.  The use of words like “must,” “must not,” “should,” and “should not” indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating physician in the context of treating the individual patient. Use of the information is voluntary.  ASCO provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

You must have an account to comment or submit evidence. Contact the Guidelines Site Administrator for assistance.


  • No labels